- Home
- VNTG vs ACTU Comparison
VNTG vs ACTU Comparison
Compare VNTG & ACTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNTG
- ACTU
- Stock Information
- Founded
- VNTG 2012
- ACTU 2015
- Country
- VNTG Singapore
- ACTU United States
- Employees
- VNTG N/A
- ACTU N/A
- Industry
- VNTG
- ACTU
- Sector
- VNTG
- ACTU
- Exchange
- VNTG NYSE
- ACTU NYSE
- Market Cap
- VNTG 118.8M
- ACTU 135.0M
- IPO Year
- VNTG 2025
- ACTU 2024
- Fundamental
- Price
- VNTG $3.91
- ACTU $7.47
- Analyst Decision
- VNTG
- ACTU Strong Buy
- Analyst Count
- VNTG 0
- ACTU 1
- Target Price
- VNTG N/A
- ACTU $20.00
- AVG Volume (30 Days)
- VNTG 1.4M
- ACTU 85.1K
- Earning Date
- VNTG 01-01-0001
- ACTU 05-15-2025
- Dividend Yield
- VNTG N/A
- ACTU N/A
- EPS Growth
- VNTG N/A
- ACTU N/A
- EPS
- VNTG N/A
- ACTU N/A
- Revenue
- VNTG $19,999,294.00
- ACTU N/A
- Revenue This Year
- VNTG N/A
- ACTU N/A
- Revenue Next Year
- VNTG N/A
- ACTU N/A
- P/E Ratio
- VNTG $25.05
- ACTU N/A
- Revenue Growth
- VNTG N/A
- ACTU N/A
- 52 Week Low
- VNTG $3.55
- ACTU $5.51
- 52 Week High
- VNTG $6.09
- ACTU $11.99
- Technical
- Relative Strength Index (RSI)
- VNTG N/A
- ACTU N/A
- Support Level
- VNTG N/A
- ACTU N/A
- Resistance Level
- VNTG N/A
- ACTU N/A
- Average True Range (ATR)
- VNTG 0.00
- ACTU 0.00
- MACD
- VNTG 0.00
- ACTU 0.00
- Stochastic Oscillator
- VNTG 0.00
- ACTU 0.00
About VNTG VANTAGE CORP
Vantage Corp specializes in providing comprehensive shipbroking services, including operational support and consultancy services, tailored to the tanker markets. The company has divided the services into various division such as Freight commission, Demurrage commission, Deviation and other commission and Sales of vessel commission.
About ACTU ACTUATE THERAPEUTICS INC
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.